Overview

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Status:
Recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin